Heat shock protein-mediated cross-presentation of exogenous HIV antigen on HLA class I and class II.
Strong CD4(+) and CD8(+) T cell responses are considered important immune components for controlling HIV infection, and their priming may be central to an effective HIV vaccine. We describe in this study an approach by which multiple CD4(+) and CD8(+) T cell epitopes are processed and presented from an exogenously added HIV-1 Gag-p24 peptide of 32 aa complexed to heat shock protein (HSP) gp96. CD8(+) T cell recognition of the HSP/peptide complex, but not the peptide alone, was inhibited by brefeldin A, suggesting an endoplasmic reticulum-dependent pathway. This is the first report to describe efficient processing and simultaneous presentation of overlapping class I- and class II-restricted epitopes from the same extracellularly added precursor peptide complexed to HSP. Given previous reports of the strong immunogenicity of HSP/peptide complexes, the present data suggest that HSP-complexed peptides containing multiple MHC class I- and class II-restricted epitopes represent potential vaccine candidates for HIV and other viral infections suitable to induce effective CTL memory by simultaneously providing CD4 T cell help.
SenGupta
Devi
D
Partners AIDS Research Center, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, USA.
Norris
Philip J
PJ
Suscovich
Todd J
TJ
Hassan-Zahraee
Mina
M
Moffett
Howell F
HF
Trocha
Alicja
A
Draenert
Rika
R
Goulder
Philip J R
PJ
Binder
Robert J
RJ
Levey
Daniel L
DL
Walker
Bruce D
BD
Srivastava
Pramod K
PK
Brander
Christian
C
D016915:AIDS Vaccines / Q000276:immunology; D000595:Amino Acid Sequence; D017951:Antigen Presentation; D015703:Antigens, CD / Q000032:analysis; D000951:Antigens, Neoplasm / Q000276:immunology*; D001402:B-Lymphocytes / Q000276:immunology; D020126:Brefeldin A / Q000494:pharmacology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology; D002461:Cell Line, Transformed; D003713:Dendritic Cells / Q000276:immunology; D018985:Epitopes, B-Lymphocyte / Q000737:chemistry / Q000276:immunology; D018984:Epitopes, T-Lymphocyte / Q000737:chemistry / Q000276:immunology; D015488:HIV Antigens / Q000276:immunology*; D016655:HIV Core Protein p24 / Q000737:chemistry / Q000276:immunology*; D015497:HIV-1 / Q000276:immunology*; D015235:HLA-B Antigens / Q000276:immunology; D006683:HLA-DQ Antigens / Q000276:immunology; D004854:Herpesvirus 4, Human; D015395:Histocompatibility Antigens Class I / Q000276:immunology*; D000949:Histocompatibility Antigens Class II / Q000276:immunology*; D006801:Humans; D026503:Low Density Lipoprotein Receptor-Related Protein-1; D008969:Molecular Sequence Data; D010446:Peptide Fragments / Q000737:chemistry / Q000276:immunology*
D016915:AIDS Vaccines; D015703:Antigens, CD; D000951:Antigens, Neoplasm; D018985:Epitopes, B-Lymphocyte; D018984:Epitopes, T-Lymphocyte; D015488:HIV Antigens; D016655:HIV Core Protein p24; C489635:HIV Gag p24 protein (29-60); D015235:HLA-B Antigens; C489636:HLA-B42 antigen; C103707:HLA-B57 antigen; D006683:HLA-DQ Antigens; C410042:HLA-DQ5 antigen; D015395:Histocompatibility Antigens Class I; D000949:Histocompatibility Antigens Class II; C475476:LRP1 protein, human; D026503:Low Density Lipoprotein Receptor-Related Protein-1; D010446:Peptide Fragments; C052646:sarcoma glycoprotein gp96 rejection antigens; D020126:Brefeldin A